In focus · trending topic

pamrevlumab

14 stories · following the connections

UPDATE - FibroGen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic Cancer

By Nasdaq OMXMar 1, 2018, 6:45 PM UTC

Fibrogen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic Cancer

By Nasdaq OMXMar 1, 2018, 12:03 PM UTC

FibroGen Reports Fourth Quarter and Full Year 2017 Financial Results

By Nasdaq OMXFeb 27, 2018, 9:11 PM UTC

FibroGen Reports Third Quarter 2017 Financial Results

By Nasdaq OMXNov 8, 2017, 9:02 PM UTC

FibroGen Granted Orphan Drug Designation for Pamrevlumab in the Treatment of Pancreatic Cancer

By Nasdaq OMXJun 22, 2017, 2:10 AM UTC

About FibroGen, Inc.FibroGen to Present at the Goldman Sachs 38th Annual Global Healthcare Conference

By Nasdaq OMXJun 13, 2017, 11:00 AM UTC

FibroGen Reports First Quarter 2017 Financial Results

By Nasdaq OMXMay 9, 2017, 8:05 PM UTC

FibroGen Reports First Quarter 2017 Financial Results

By Nasdaq OMXMay 9, 2017, 8:05 PM UTC